Preferred salvage regimens for Ibrutinib and Idelalisib-Rituximab

Susan M. O’Brien, MD of University of California Irvine the preferred salvage regimens for Ibrutinib and Idelalisib-Rituximab at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego.

www.scrippshealth.org/cancer